Medivir interim report, 1 january -30 june 2001

MEDIVIR INTERIM REPORT, 1 January - 30 June 2001 · Profit after financial items was SEK -68.0 (-33.9) m; net sales increased to SEK 63.6 (54.7) m. · CCS lifted its net sales to SEK 63.8 (41.2) m; operating profit was SEK 9.7 (8.7) m. · Herpes antiviral ME-609: Final Report from the phase II clinical trial showed good efficacy. Strategy for outlicensing and phase III clinical trial strategy established. · Multiresistant-HIV antiviral MIV-310: Authorization to commence phase II clinical trials received. · Good progress in the preclinical portfolio. Forthcoming Reports in 2001 The nine-month Interim Report will be published on 31 October. These Reports will be available on Medivir's Website on these dates under the heading 'Financial Information'. For more information, please contact: Jonas Frick, CEO and President: +46 (0)8 608 3117 Rein Piir, CFO / VP IR: +46 (0)8 608 3123, cellphone +46 (0)708 53 7292 Medivir AB, Lunastigen 7, 141 44 Huddinge, Sweden Tel. +46 (0)8 608 3100, e-mail:, The Medivir group The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB (formerly Jillprodukter). Medivir is an innovative specialist pharmaceuticals research and development corporation. Medivir's research is focused on developing compounds into new pharmaceuticals based on proteases and polymerases as target enzymes. Medivir's research concentrates primarily on infectious diseases and autoimmune disorders. The research portfolio comprises projects against HIV, viral hepatitis, shingles, cold sores, osteoporosis and autoimmune disorders. Medivir has five projects in clinical development phases, two of which are entering phase III after completing phase II. Two are in phase I and one project is entering phase II. Medivir's preclinical research encompasses a number of projects, of which two are in their lead optimization phase and one is entering the late preclinical stage. ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report The full report

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).